Stocks and Investing Stocks and Investing
Tue, February 23, 2021

Brian Skorney Upgraded (VRTX) to Buy and Increased Target to $252 on, Feb 23rd, 2021


Published on 2024-10-27 15:43:54 - WOPRAI, Brian Skorney
  Print publication without navigation


Brian Skorney of Baird, Upgraded "Vertex Pharmaceuticals Incorporated" (VRTX) to Buy and Increased Target from $220 to $252 on, Feb 23rd, 2021.

Brian has made no other calls on VRTX in the last 4 months.



There are 10 other peers that have a rating on VRTX. Out of the 10 peers that are also analyzing VRTX, 2 agree with Brian's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Geoffrey Porges of "SVB Leerink" Maintained at Hold with Decreased Target to $250 on, Tuesday, February 2nd, 2021
  • Matthew Harrison of "Morgan Stanley" Maintained at Hold with Increased Target to $251 on, Tuesday, January 19th, 2021


These are the ratings of the 8 analyists that currently disagree with Brian


  • Brian Abrahams of "RBC Capital" Maintained at Buy and Held Target at $264 on, Monday, February 15th, 2021
  • Do Kim of "BMO Capital" Maintained at Buy with Decreased Target to $284 on, Tuesday, February 2nd, 2021
  • Edward Tenthoff of "Piper Sandler" Maintained at Buy with Increased Target to $347 on, Tuesday, February 2nd, 2021
  • Evan Seigerman of "Credit Suisse" Maintained at Buy with Decreased Target to $280 on, Tuesday, February 2nd, 2021
  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $288 on, Friday, November 20th, 2020
  • Vincent Chen of "Bernstein" Initiated at Buy and Held Target at $275 on, Friday, November 20th, 2020
  • Paul Matteis of "Stifel" Maintained at Strong Buy with Decreased Target to $277 on, Friday, October 30th, 2020
  • Gena Wang of "Barclays" Maintained at Buy with Decreased Target to $307 on, Friday, October 30th, 2020
Contributing Sources